Gene Editing’s Promise Comes With Permanent Risks

A one-time treatment is an alluring medical idea

Gene-editing and gene-therapy technologies are raising the prospect that some people could one day manage disease with a single treatment rather than years or decades of daily medication. The potential is especially striking for common conditions such as high cholesterol, heart disease, obesity and diabetes, where treatment often depends on long-term adherence to drugs and ongoing clinical care.

But the same feature that makes a genomic treatment compelling—its potential durability—also makes it unusually difficult to evaluate. A change intended to last for decades may bring benefits for decades, but unwanted effects could be lasting too. Researchers at the University of Michigan Health Frankel Cardiovascular Center argue that long-term safety must be central before such interventions are offered broadly.

In a perspective published in JAMA Internal Medicine, cardiologists Eric D. Smith and Venkatesh L. Murthy examine how clinicians and researchers should weigh the promise of genomic therapies against the risks of making permanent changes to genetic activity. Their focus is not on a single product. It is on the larger transition from treatments that can be stopped or adjusted to interventions designed to keep working after one administration.

What makes genomic treatment different

Conventional medicines generally work only while patients continue taking them. Their dose can be changed, the drug can be discontinued and side effects may fade after treatment stops. Genetic therapies operate on a different premise. They may introduce working copies of genes, silence harmful genetic activity or make changes directly to DNA.

That approach can offer a major practical advantage. If a treatment can safely maintain a beneficial biological effect after one dose, it could reduce the burden of repeated medication and help people who struggle with sustained access or adherence. A durable therapy might also reshape how health systems think about prevention, moving some care from continuous management toward a long-lasting intervention.

Yet permanence changes the clinical bargain. When an effect cannot readily be reversed, uncertainty matters more. The researchers warn that risks may emerge over years, and that the challenge is not only whether an edit produces the intended result immediately. It is whether the altered genetic activity remains safe across a person’s life.

Success in rare disease does not erase the next challenge

Gene therapy has already delivered important results for serious illnesses, including spinal muscular atrophy and sickle cell disease. Those successes demonstrate that genetic approaches can make a meaningful difference when conventional options are limited or when disease burden is profound.

Expanding the model to widespread chronic conditions is a much larger undertaking. More than 6,000 rare genetic disorders have been identified, though only a small portion currently have treatment targets. The potential population for treatments aimed at cholesterol, cardiovascular disease, obesity or diabetes would be far greater than for many rare-disease therapies.

That scale raises the evidentiary bar. A therapy considered for people with severe illness and few alternatives may be assessed differently from one proposed for large numbers of people who may have effective existing medicines. For common disease, even uncommon adverse outcomes can affect many patients once use becomes widespread.

Questions before broad adoption

The Michigan researchers’ perspective centers on careful evaluation rather than a rejection of genomic medicine. Its message is that scientific ambition must be matched by methods to identify, monitor and understand harms that could take a long time to become visible.

Clinical studies will need to establish more than short-term biological success. They will need to follow participants long enough to detect delayed outcomes and determine whether benefits remain durable. Researchers and regulators will also need to consider which patients are appropriate candidates and how to compare an irreversible intervention with drugs that can be adjusted as a person’s health changes.

In cardiovascular prevention, that comparison is particularly important. Daily medication can be imperfect, but it also permits flexibility. A clinician can alter treatment in response to side effects, new evidence or changing risk. A durable genomic intervention may offer a different kind of benefit, but it reduces that ability to revise course later.

• Gene therapies can add functional genes, silence harmful activity or directly alter DNA.
• One-time treatments may reduce dependence on repeated medication.
• Permanent effects demand monitoring for risks that may take years to emerge.
• Broad use in common disease requires a different scale of evidence than rare-disease treatment.

Promise should be paired with patience

The prospect of preventing disease for decades with one intervention is a powerful one. It could change the experience of chronic care for patients and reshape the economics and logistics of treatment. It could also broaden the reach of medicine beyond treating symptoms to modifying underlying biology.

But irreversible medical changes require confidence that cannot be inferred from early results alone. The researchers’ caution is a reminder that the goal is not merely to make gene editing possible in more settings. It is to establish when it is justified, for whom it is appropriate and how its consequences can be responsibly tracked over time.

For now, genomic medicine’s most consequential question may be the one posed by the researchers: not simply whether scientists can permanently alter genetic activity, but whether the expected benefit is sufficient to justify the uncertainty that permanence creates.

This article is based on reporting by Science Daily. Read the original article.